Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer

Table 5 Univariate and multivariable Cox regression model for TTP according to dichotomised IC₅₀ drug sensitivity values (above or below the median value) and clinicopathological variables for the CRC subgroup

n = 47	Median TTP	Log-rank	Univariate	Univariate	Multivariate
n = 47	Months	p	HR	p	p
Treated vs. untreated	10 vs. 5	0.06	0.5	0.2	-
Oxaliplatin ^†	5 vs. 5	0.8	0.9	0.9	-
Cisplatin ^†	5 vs. 5	0.8	0.9	0.9	-
Melphalan ^†	12 vs. 7	0.8	1.1	0.8	-
5-FU ^†	6 vs. 5	0.7	0.9	0.7	-
Mitomycin C ^†	12 vs. 4	0.2	0.6	0.2	-
Irinotecan ^†	5 vs. 5	0.9	1.0	0.9	-
Docetaxel ^†	10 vs. 4	0.6	0.8	0.6	-
Doxorubicin ^†	12 vs. 1	0.008	0.4	0.009	0.02
Synch. vs. Metach.	9 vs. 4	0.05	0.5	0.05	0.006
Vasc./neural vs. not	2 vs. 10	0.05	2.3	0.03	0.12
Mucinous vs. not	9 vs. 5	0.12	0.6	0.12	-
Lymph node + vs. not	6 vs. 7	0.9	1.0	0.9	-
CC0 vs. CC 1-3	18 vs. 4	0.002	0.3	0.001	0.002

There was missing data concerning TTP in 5 patients.
^† Below vs. above the median IC₅₀ value. Low IC₅₀ indicates better sensitivity.
Abbreviations: TTP time to progression, CRC colorectal cancer, Synch synchronous, metach metachronous, vasc/neural vascular or neural invasion, CC completeness of cytoreduction.

ISSN: 1471-2407